Navigation Links
Enrollment for Medicare IVIG Demonstration Project Begins August 8, 2014
Date:8/6/2014

TOWSON, Md., Aug. 6, 2014 /PRNewswire/ -- The Immune Deficiency Foundation (IDF) is pleased to announce that the enrollment for the Medicare IVIG Demonstration Project will begin on August 08, 2014. The enrollment period will end on September 12, 2014, so patients should act quickly to sign up. If approved, a beneficiary receiving an IVIG home infusion after October 01, 2014 will be covered. Medicare will inform all applicants by September 30th of their status.

Patients who are covered under Medicare Fee-For-Service and enrolled in Part B; have a diagnosis of primary immunodeficiency (PI); and are not currently covered under a home health episode of care, are eligible for enrollment. Interested participants should complete, sign and submit an enrollment application to be considered for the demonstration project, and they can do so at http://www.medicarenhic.com.

If enrolled in the IVIG demonstration, Medicare will pay a bundled payment for supplies and related nursing services to administer patients IVIG medication in the home. Participation in the demonstration will not affect any other Medicare benefits, participation is voluntary – and participants can withdraw at any time.

In January 2013, the Medicare IVIG Access Act (HR 1845) was signed into law by President Barack Obama, creating a three-year demonstration project allowing for the payment of home infusion services for Medicare patients with PI.

"IDF strived for years to have the legislation passed that would help cover the costs of home infusion in the Medicare law, and we are thrilled that the demonstration project is beginning," said Marcia Boyle, IDF President & Founder. "Patients with primary immunodeficiency diseases should have the right to access to all sites of care including the right to be infused in the home setting if that is medically appropriate."

The demonstration project should prove the cost effectiveness of allowing Medicare patients with PI access to home infusions of IVIG, thus paving the way for a permanent fix to this issue.

For more information, or to get a copy of the enrollment application, visit http://www.medicarenhic.com, or call (844)-625-6284. Please note that submitting an application for this demonstration does not guarantee that a patient will be selected to participate.


'/>"/>
SOURCE Immune Deficiency Foundation
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Generex Announces Completion of Enrollment of Antigen Express Phase II AE37 Breast Cancer Vaccine Trial
2. Verified Clinical Trials Stops Dual Enrollment in Clinical Trials in Major CNS Clinical Trials to Reduce Potential Adverse Events and Improve Data Quality
3. Major CRO Gives Top Ratings To Verified Clinical Trials To Stop Dual Enrollment In Clinical Trials On Late Phase Trial
4. AtheroNova Completes Enrollment in Phase 1 Clinical Trial of AHRO-001, a Potential Treatment for Atherosclerosis
5. Verified Clinical Trials Selected to Prevent Dual Enrollment in Clinical Trials, Will Add Over 800 Additional Sites for a New Phase 3 North American Clinical Trial
6. TrialNetworks Customer to Present Results of Using Site Engagement Technology to Improve Study Operations and Patient Enrollment at Clinical Trial Optimization Conference
7. Study Scavenger and CenterWatch Partner to Improve Patient Recruitment, Enrollment and Mobile Access to Clinical Trials with New Study Scavenger Smartphone App
8. Ohr Pharmaceutical Achieves 50% Enrollment Milestone in Squalamine Eye Drop Phase II Clinical Trial
9. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
10. Spaulding Clinical Research Partners With Verified Clinical Trials Protecting Clinical Trials From Dual Enrollment
11. NeuroDerm Announces Enrollment in a Phase 2 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2016)... Calif. (PRWEB) , ... May 18, 2016 , ... ... awarded the Luis Villalobos Award to Cognition Therapeutics at the annual ACA Summit last ... company that is financed by one of ACA’s member angel groups. It is the ...
(Date:5/18/2016)... , May 18, 2016 The Biotech ... does not mean that there are no opportunities ahead. Today, ... Inc. (NASDAQ: THLD ), Seattle Genetics Inc. (NASDAQ: ... ), and Ophthotech Corp. (NASDAQ: OPHT ). Sign ... at: http://www.activewallst.com/ Threshold Pharmaceuticals ...
(Date:5/18/2016)... ... 18, 2016 , ... Every day, more than 5,400 ER ... Costing more than $56 billion in direct costs annually, asthma remains a critical ... the suffering associated with uncontrolled asthma can be overwhelmingly disproportionate and better managed,” ...
(Date:5/18/2016)... ... ... Ryan Benton was diagnosed with Duchenne Muscular Dystrophy (DMD) at the age ... DMD is a relatively common progressive genetic disorder, which causes aggressive deterioration of the ... He met with the founder of the Stem Cell Institute in Panama ...
Breaking Biology Technology:
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... provide their customers enhanced security to access and ...
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
Breaking Biology News(10 mins):